See more : Generex Biotechnology Corporation (GNBTQ) Income Statement Analysis – Financial Results
Complete financial analysis of Art Vivant Co., Ltd. (7523.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Art Vivant Co., Ltd., a leading company in the Personal Products & Services industry within the Consumer Cyclical sector.
- Everbridge, Inc. (EVBG) Income Statement Analysis – Financial Results
- Blueberries Medical Corp. (BBM.CN) Income Statement Analysis – Financial Results
- Orora Limited (ORRYY) Income Statement Analysis – Financial Results
- PT Capitol Nusantara Indonesia Tbk (CANI.JK) Income Statement Analysis – Financial Results
- Avisana Corp. (AVSA) Income Statement Analysis – Financial Results
Art Vivant Co., Ltd. (7523.T)
About Art Vivant Co., Ltd.
Art Vivant Co., Ltd. operates in the art business. The company sells paintings, including printed, oil painting, and watercolor products; and arts and crafts, such as sculptures and glass crafts, as well as miscellaneous art goods. It also engages in yoga / fitness and finance business. The company provides credit products; and operates CARNA, a resort and fitness club, as well as Amida for lava hot yoga. Art Vivant Co., Ltd. was incorporated in 1971 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 11.01B | 10.72B | 10.25B | 7.89B | 8.77B |
| Cost of Revenue | 3.90B | 3.77B | 3.74B | 2.94B | 3.29B |
| Gross Profit | 7.10B | 6.96B | 6.51B | 4.95B | 5.48B |
| Gross Profit Ratio | 64.54% | 64.88% | 63.53% | 62.78% | 62.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.20B | 3.26B | 3.01B | 2.57B | 2.56B |
| Selling & Marketing | 1.54B | 1.45B | 1.34B | 964.00M | 1.02B |
| SG&A | 4.74B | 4.71B | 4.35B | 3.54B | 3.58B |
| Other Expenses | 0.00 | 10.77M | -12.26M | 9.53M | 0.00 |
| Operating Expenses | 4.74B | 4.71B | 4.35B | 3.54B | 3.75B |
| Cost & Expenses | 8.64B | 8.48B | 8.09B | 6.47B | 7.05B |
| Interest Income | 47.44M | 7.91M | 13.86M | 10.57M | 15.98M |
| Interest Expense | 68.83M | 65.30M | 68.23M | 68.40M | 62.88M |
| Depreciation & Amortization | 122.93M | 134.35M | 164.56M | 190.51M | 187.00M |
| EBITDA | 3.04B | 2.04B | 2.21B | 1.35B | 2.09B |
| EBITDA Ratio | 27.63% | 23.32% | 24.60% | 21.26% | 23.80% |
| Operating Income | 2.36B | 2.25B | 2.16B | 1.41B | 1.90B |
| Operating Income Ratio | 21.48% | 20.96% | 21.06% | 17.91% | 21.66% |
| Total Other Income/Expenses | 484.97M | -406.23M | -179.21M | -478.98M | -123.06M |
| Income Before Tax | 2.85B | 1.84B | 1.98B | 933.24M | 1.68B |
| Income Before Tax Ratio | 25.89% | 17.17% | 19.32% | 11.83% | 19.17% |
| Income Tax Expense | 1.08B | 487.54M | 830.31M | 504.25M | 619.00M |
| Net Income | 1.77B | 1.35B | 1.15B | 428.99M | 1.06B |
| Net Income Ratio | 16.05% | 12.63% | 11.22% | 5.44% | 12.11% |
| EPS | 163.77 | 123.83 | 106.91 | 40.50 | 91.59 |
| EPS Diluted | 163.77 | 123.83 | 106.91 | 40.50 | 91.59 |
| Weighted Avg Shares Out | 10.78M | 10.94M | 10.76M | 10.59M | 11.59M |
| Weighted Avg Shares Out (Dil) | 10.78M | 10.94M | 10.76M | 10.59M | 11.59M |
Source: https://incomestatements.info
Category: Stock Reports